ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Shares Down 3.2% – Time to Sell?

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) dropped 3.2% during trading on Thursday . The stock traded as low as $67.94 and last traded at $68.56. 51,634 shares traded hands during mid-day trading, an increase of 37% from the average daily volume of 37,809 shares. The stock had previously closed at $70.79.

ALPS Medical Breakthroughs ETF Trading Down 3.2%

The stock has a fifty day simple moving average of $63.89 and a two-hundred day simple moving average of $56.41.

Hedge Funds Weigh In On ALPS Medical Breakthroughs ETF

Several hedge funds have recently bought and sold shares of the company. Exencial Wealth Advisors LLC increased its holdings in ALPS Medical Breakthroughs ETF by 3.2% during the 4th quarter. Exencial Wealth Advisors LLC now owns 8,101 shares of the company’s stock worth $415,000 after acquiring an additional 248 shares during the period. Royal Bank of Canada boosted its holdings in ALPS Medical Breakthroughs ETF by 2.8% in the 4th quarter. Royal Bank of Canada now owns 12,269 shares of the company’s stock valued at $628,000 after purchasing an additional 330 shares during the period. Harbor Investment Advisory LLC purchased a new position in shares of ALPS Medical Breakthroughs ETF during the 2nd quarter valued at $29,000. Steward Partners Investment Advisory LLC purchased a new position in shares of ALPS Medical Breakthroughs ETF during the 4th quarter valued at $26,000. Finally, Griffin Asset Management Inc. grew its position in shares of ALPS Medical Breakthroughs ETF by 1.9% during the 4th quarter. Griffin Asset Management Inc. now owns 30,699 shares of the company’s stock valued at $1,572,000 after purchasing an additional 564 shares in the last quarter.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.